The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication.
Douglas Losordo, director of the Feinberg Cardiovascular Research Institute, will serve as the principal investigator of the study.
Ronald Berninger, chief scientific officer of CellCyte, said: “This is another important collaboration for our program, as it allows us to evaluate the functional outcome benefit of the CCG-TH30 therapy as compared to standard cell therapies where delivery agents aren’t used.”